TARA

Rating neutralAI Memo

Protara Therapeutics

As of 2026-09-03/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

ADVANCED-2 enrollment and ADVANCED-3 redesign milestones • 2026-12-02

Base target: $5 / p=50% prob

Biggest risk

The Q2 per-share loss reportedly missed consensus [#PR-EARNINGS-2026-08-11], and the investment case remains dependent on binary clinical and regulatory execution. ADVANCED-3 is being redesigned, which may broaden opportunity but also adds uncertainty around comparability and timing. A June 2026 CEO open-market sale following an option exercise is a secondary sentiment and supply risk, not evidence about operating performance [#SEC-FORM4-2026-07-01].

Invalidation

Break below $2 or thesis failure.

What would change my mind?

Multiple late-stage programs provide several potential 4Q 2026 catalysts, while reported cash and investments of approximately $162 million are expected by management to support planned operations into 2028 [#SEC-8K-2026-08-11]. Successful enrollment, interim efficacy or safety data, and progress toward the planned LM BLA could re-rate the stock.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-03

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-Q2 earnings digestion remains a near-term overhang
STARBORN-1 completion and planned LM BLA
Multiple late-stage programs provide several potential 4Q 2026 catalysts, while reported cash and investments of approximately $162 million are expected by management to support planned operations into 2028 [#SEC-8K-2026-08-11].

BearKey bullets

Clinical-stage cash burn, future financing, and dilution risk despite management's stated runway into 2028.
Delays, enrollment challenges, or unfavorable efficacy and safety data in ADVANCED-2, ADVANCED-3, STARBORN-1, or THRIVE-3.
Insider open-market selling by the CEO may add supply pressure, although it is not evidence of business deterioration [#SEC-FORM4-2026-07-01].

WatchKey bullets

ADVANCED-2 enrollment and ADVANCED-3 redesign milestones

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $5 (p=50%)

Target spread vs base: +67% / -51%

Scenario probabilities

Bull Target: $8 (p=25%)Base Target: $5 (p=50%)Bear Target: $2 (p=25%)

Commentary

The evidence supports a cautious monitoring view. The latest company filing preserves several 4Q 2026 milestones and a stated cash runway, but the recent earnings miss, low coverage, lack of dependable analyst revision data, binary clinical risk, and limited direct peer evidence argue against a high-conviction bullish stance. Social and options data are unavailable; the neutral placeholder values are not treated as evidence.

As of 2026-09-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-Q2 earnings digestion remains a near-term overhang
STARBORN-1 completion and planned LM BLA

Scenarios

Bull Target (Scenario probability)

$8 / p=25% prob

Base Target (Scenario probability)

$5 / p=50% prob

Bear Target (Scenario probability)

$2 / p=25% prob

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-02
ADVANCED-2 enrollment and ADVANCED-3 redesign milestones
Protara expects to complete enrollment of the BCG-unresponsive ADVANCED-2 registrational cohort in 4Q 2026 and is redesigning ADVANCED-3 as a broader exploratory study. Execution could improve confidence in the NMIBC program, while delay or weaker data would reinforce the wait-and-see stance [#SEC-8K-2026-08-11].
Prob 60.00% • Move 22.00% • Priced-in 40.00%
EVENT2026-12-02
THRIVE-3 interim results
The company remains on track to report interim results from the registrational THRIVE-3 trial of IV Choline Chloride in 4Q 2026, creating a potentially material but binary clinical readout [#SEC-8K-2026-08-11].
Prob 55.00% • Move 25.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Post-Q2 earnings digestion remains a near-term overhang
2026-09-30
Stored earnings context reported a Q2 loss of $0.36 per share versus a $0.33 analyst estimate, leaving near-term sentiment vulnerable despite continued pipeline progress [#PR-EARNINGS-2026-08-11].
Prob 65% • Move -8% • Priced-in 55%

Long-term Catalysts

Months to a year

STARBORN-1 completion and planned LM BLA
2027-09-03
Protara expects an update and enrollment completion for STARBORN-1 in 4Q 2026 and intends to submit a TARA-002 BLA for lymphatic malformations in 2H 2027. Cash, cash equivalents and investments were approximately $162 million as of June 30, 2026, with planned operations expected to extend into 2028 [#SEC-8K-2026-08-11].
Prob 50% • Move 45% • Priced-in 25%

Risks

Clinical-stage cash burn, future financing, and dilution risk despite management's stated runway into 2028.
Delays, enrollment challenges, or unfavorable efficacy and safety data in ADVANCED-2, ADVANCED-3, STARBORN-1, or THRIVE-3.
Insider open-market selling by the CEO may add supply pressure, although it is not evidence of business deterioration [#SEC-FORM4-2026-07-01].
Q2 earnings missed the cited consensus estimate, and the stock may remain sensitive to small-cap biotech risk appetite.
Regulatory uncertainty around the planned TARA-002 BLA for lymphatic malformations and future NMIBC development.

Peers

Symbol	Summary
AKBA	Loose same-sector market-cap peer; useful for small-cap biotechnology capital-markets context but not a direct clinical comparator.
ARCT	Loose same-sector market-cap peer; relevant for event-driven clinical-biotech volatility, though program and indication overlap is limited.
IPHA	Loose same-sector market-cap peer; provides broad biotechnology valuation context rather than a close operating comparison.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-03

Loading AI feed…

Symbol

Summary

AKBA

Loose same-sector market-cap peer; useful for small-cap biotechnology capital-markets context but not a direct clinical comparator.

ARCT

Loose same-sector market-cap peer; relevant for event-driven clinical-biotech volatility, though program and indication overlap is limited.

IPHA

Loose same-sector market-cap peer; provides broad biotechnology valuation context rather than a close operating comparison.